Trends in non-receipt of recommended COPD medication

TY - JOUR

T1 - Trends in non-receipt of recommended COPD medication

AU - Poon, Michael

AU - Pequeno, Priscila

AU - Aaron, Shawn D.

AU - Stanbrook, Matthew B.

AU - Wong, Harvey H.

AU - Cram, Peter

AU - Gershon, Andrea S.

N1 - Funding Information: Conflict of interest: M. Poon has nothing to disclose. P. Pequeno has nothing to disclose. S.D. Aaron reports personal fees from GSK, Sanofi and AstraZeneca, outside the submitted work. M.B. Stanbrook has nothing to disclose. H.H. Wong reports that Becton Dickinson provides funds that help support the advanced pulmonary procedures fellowship at his institution. Cook Medical provides support for simulation courses H.H. Wong runs for pulmonary trainees in Toronto. P. Cram has nothing to disclose. A.S. Gershon reports grants from Government of Ontario and the Canadian Respiratory Research Network during the conduct of the study. Funding Information: Acknowledgements: Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors and not necessarily those of CIHI. We thank IQVIA Solutions Canada Inc. for use of their Drug Information Database. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). The opinions, results and conclusions reported in this paper are those of the authors, and are independent from the funding sources. No endorsement by ICES or the Ontario MOH or MLTC is intended or should be inferred. Funding Information: Support statement: This research was funded by a Health Systems Research Fund Capacity Award provided by the Government of Ontario, Canada. It was also funded by the Canadian Respiratory Research Network, which is supported by grants from the Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health, the Canadian Lung Association/Canadian Thoracic Society, the British Columbia Lung Association; and industry partners Boehringer Ingelheim Canada Ltd, AstraZeneca Canada Inc. and Novartis Canada Ltd. Funding for training of graduate students and new investigators within the network was supported by the above funding sponsors and as well by GlaxoSmithKline Inc. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. A.S. Gershon is funded through a CIHR New Investigator Award and was funded by a Physicians Services Incorporated Fellowship in Translational Medicine while working on this study. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors and not necessarily those of CIHI. We thank IQVIA Solutions Canada Inc. for use of their Drug Information Database. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). The opinions, results and conclusions reported in this paper are those of the authors, and are independent from the funding sources. No endorsement by ICES or the Ontario MOH or MLTC is intended or should be inferred.

PY - 2022/4/1

Y1 - 2022/4/1

UR - https://www.scopus.com/pages/publications/85129733124

UR - https://www.scopus.com/pages/publications/85129733124#tab=citedBy

U2 - 10.1183/23120541.00584-2021

DO - 10.1183/23120541.00584-2021

M3 - Letter

C2 - 35479295

AN - SCOPUS:85129733124

SN - 2312-0541

VL - 8

JO - ERJ Open Research

JF - ERJ Open Research

IS - 2

M1 - 00584-2021

ER -